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Plasma exudation has been suggested to be an important component of the inflammatory response in asthma.
Bradykinin elicits many of the features of asthma, including bronchoconstriction, cough, plasma exudation and
mucus secretion. In an attempt to quantify local plasma exudation, we have employed a novel low-trauma technique
with the aim of challenging and lavaging a central part of the bronchial tree, by selecting a medium sized bronchus.
A fibreoptic bronchoscopy was performed in non-smoking healthy volunteers. The instrument was placed
proximally in the right upper lobe bronchus. A plastic catheter, equipped with an inflatable latex balloon, was
inflated with air (2–4 cmH2O). A solution (100 ml of either two different concentrations of bradykinin: 0?09 and
0?9mgml71; or normal saline) was instilled through the catheter and distal to the balloon. Eight minutes later a
lavage procedure with 10ml of saline was performed through the catheter. The procedure was then repeated twice,
with the other solutions, but from the lingular and middle lobe bronchi. All solutions were given in a blinded
fashion, and two different studies were performed. Lavage concentrations of albumin and IgG were quantified as
measurements of plasma exudation.
In our first study we found that bradykinin challenge significantly increased concentrations of albumin and IgG.
In study two, there was no numeric increase in plasma proteins after local bradykinin challenge, but the
concentration of thromboxane was significantly increased in lavages from bradykinin-challenged bronchi.
Thus, local bronchial administration of bradykinin has the capacity to induce exudation of large plasma
macromolecules into the bronchial lumen, as well as local thromboxane production.
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Plasma exudation from the bronchial micro-vasculature into
the airway wall and lumen is considered to be one important
factor possibly contributing to airflow obstruction and
bronchial hyper-responsiveness in asthmatic patients. The
extravasated plasma may cause oedema of the mucosa and
may also contribute to mucus production (1,2).
Asthmatic triggers like allergen have been shown to
increase the concentration of plasma macromolecules in
bronchial lumen (3–6). The mechanisms of plasma exuda-Received 22 May 2000 and accepted in revised form 2 January
2001.
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but only to a limited degree in humans (3,7–9).
Bradykinin elicits many of the features of asthma,
including bronchoconstriction, cough, plasma exudation
and mucus secretion, and this mediator has therefore been
suggested to be involved in this disease (10–14). Bradykinin
is produced by tissue and plasma kallikreins from kinino-
gen. There is evidence for kinin activity in bronchoalveolar
lavage fluid from asthmatic patients (15,16), supporting
an earlier report of increased kinin activity during
asthmatic attacks (17). Bradykinin produces airway smooth
muscle contraction and exudation of plasma partly by the
release of secondary mediators (10,18,19). Thus, bradykinin
has the capacity to induce release of acetylcholine from
cholinergic nerves, tachykinins from sensory nerves, and
can also induce production of thromboxane from possibly
platelets, macrophages and neutrophils present in the
airways (20–22). The exact role of bradykinin in asthma
will however only become apparent when potent and
selective antagonists are available for clinical tests.# 2001 HARCOURT PUBLISHERS LTD
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bradykinin has the capacity to induce exudation of plasma
in human airways, and whether thromboxane is produced
in response to bradykinin challenge. To test this, we utilized
a bronchoscopy technique to challenge and lavage locally a
central part of a medium-sized bronchus, using a low-
pressure balloon catheter. Local challenge was performed
by instillation of different doses of bradykinin via the
catheter. The challenged area was then lavaged through the
same catheter, and levels of plasma proteins and throm-




Two studies were performed, and both were approved by
the local Ethics Committee of Go¨teborg and Lund
Universities respectively, in accordance with Helsinki
Declaration II. Healthy, non-smoking volunteers were
included in the studies. No subject had any history of
asthma or allergy, and had not suffered from any
respiratory infection within 4 weeks prior to the study.
The subjects were given both verbal and written informa-
tion, and were included for participation in the study only
after informed consent. We followed the guidelines for
fibrebronchoscopy and bronchoalveolar lavage recom-
mended by the European Society of Pneumology (25).
At visit one, subjects underwent a physical examination.
At the next visit they came to the bronchoscopy unit early
in the morning. All subjects were premedicated with
atropine 0?5mg subcutaneously and diazepam 10mg
rectally. The bronchoscopy was performed in a supine
position and under local anaesthesia (lidocaine) according
to a standard procedure. During the bronchoscopy, they
were monitored for cardiac arrhythmia with a electro-
cardiogram, and for oxygen saturation by finger probe
oximetry.
The instrument (a flexible fibreoptic bronchoscope,
Olympus Corporation of America) was inserted orally
and intermittent doses of lidocaine (40mgml71) were
sprayed on the vocal cords and into the bronchial tree,
with the standardized total dose of 8?0ml. The segment for
challenge was then randomly assigned according to a
predetermined assigned schedule. We used only the right
upper lobe bronchus, the right middle lobe bronchus, and
the lingular bronchus for challenge with bradykinin or
vehicle. A plastic catheter, equipped with an inflatable latex
balloon at the distal end, was inflated with 0?6–0?8ml air,
which gave a balloon pressure of 2–4 cm H2O. The catheter
has two channels: one for inflation of the balloon with air
and one for solutions for challenge and lavage.
In a small, preliminary dose-finding study, we found that
the concentration of 9mgml71 of bradykinin (0?1ml)
caused rapid flushing, nausea, tachycardia and general
discomfort in one of three subjects tested. For the studies
now presented, we therefore chose to give 0?1ml of either
0?09 and 0?9mgml71 bradykinin, or normal saline, byinstillation through the catheter. The very small volume for
challenge was chosen to minimize the provoked area,
because we have found in earlier studies that even 2ml
penetrates out to the pleural surface. Eight minutes later the
lavage procedure was performed with 10ml of saline
flushed via the catheter. Immediately hereafter, fluid was
aspirated (using a 25-ml syringe and hand suction only).
The procedure was then repeated twice with the other
solutions, but now using the other bronchi. These three
bronchi were selected to achieve maximum recovery. In a
supine position, the solution will drain towards the main
bronchi by gravitational force. This ensures the best
possible return after flooding them with saline. After
aspiration, the balloon was deflated and the mucosa was
inspected for possible pressure-induced lesions by the
balloon. The bronchoscope was then removed.
Figure 1 shows the distribution of contrast medium
(barium sulphate) instilled into the middle lobe bronchus
1 and 8min after instillation through the catheter. Thus, the
liquid remains in the close vicinity of the tip of the catheter
for at least 8min.
Two studies were performed. In study one, we selected
eight subjects (three women), aged 21–48 years (median, 28
years), and in study two, we selected 11 subjects (seven
women), aged 22–46 years (median, 36 years).
In study two, subjects underwent two bronchoscopies,
with an interval of at least 14 days. They were randomized
(double-blind) to a treatment with inhaled placebo or
formoterol 24 mg (two puffs 12 mg) 1 h ahead of the two
procedures. Apart from this, the procedures were identical
to study one.
CHALLENGE SOLUTION
Bradykinin (Nova Biochem Ltd, Nottingham, U.K.) was
dissolved in ethanol (10%) and 0?9% sodium chloride to
produce a concentration of 0?09 and 0?9mgml71 respec-
tively. The purity of the synthetic kinin was con-
firmed by high performance liquid chromatography.
CHALLENGE PROCEDURE
Bradykinin or vehicle was given to the bronchus distal to
the balloon in a blinded fashion. The procedure was
performed in the right upper lobe bronchus, the right
middle lobe bronchus, or the lingular bronchus, in a
randomized order. The bronchial lavage was performed
8min after administration of bradykinin or vehicle.
MEASUREMENTS OF LAVAGE PROTEINS
AND TXB2
Lavage concentrations of albumin and IgG were quantified
as a measurement of plasma exudation, and TXB2 was
quantified as a measurement of TX production.
Albumin in lavage fluid was assayed using an nephelo-
metry method sensitive to 1mgml71, IgG was assayed
using an nephelometry method, sensitive to 4mgml71.
FIG. 1. Distribution of contrast medium (barium sulphate) instilled into the middle lobe bronchus (a) 1 and (b) 8min after
instillation through the catheter.
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Chemistry, Sahlgrenska University Hospital.
TxB2 was quantified using an ELISA kit (R&D Systems,
Abingdon, Oxon, U.K.), with a sensitivity 47?98 pgml71
(range 13?7–10 000 pgml71).
STATISTICAL ANALYSES
Differences between concentrations of macromolecules and
thromboxane were evaluated using paired non-parametric
tests, comparing the concentration of lavages from vehicle
and bradykinin exposed bronchi. A P-value less than 0?05
was considered to be significant.
Results
All subjects tolerated the bronchoscopy well without any
complications or macroscopic lesions in the mucosa.
Bradykinin doses (0?09 and 0?9mgml71) did not cause
obvious systemic effects.
The mean fluid recovery during lavage, expressed as
mean percentage of performed lavages, was not different
between vehicle and bradykinin-challenged bronchi (11?2%
and 10?7% respectively).
The concentrations of albumin and IgG were signifi-
cantly increased after bradykinin challenge compared to the
control dilution-challenged bronchi, in lavages acquired
during study one (Figs 2 and 3). Albumin levels were raised
by 77% and 112% after 0?09 and 0?9mgml71 bradykinin
respectively. IgG levels showed the same pattern of increase
(Fig. 3).In study two, one patient was excluded from the study
analysis because of the requirement of excessive local
anaesthesia during the bronchoscopic procedure (see
Methods). There was no numeric increase in serum
macromolecules in the lavage fluid after local bradykinin
challenge vs. vehicle in this second experiment, and there-
fore no further statistical analyses were performed. How-
ever, the concentration of thromboxane was significantly
increased in lavages from bradykinin-challenged bronchi
compared to vehicle (Fig. 4).
Discussion
In this paper, we describe the findings from two studies in
man, that have evaluated the effects of local airway
bradykinin challenge on airway exudation of plasma
macromolecules into the airway lumen, and the levels of
thromboxane. One of these studies show that bradykinin
cause significant plasma exudation, and the other study
show that bradykinin cause significant increase in the
concentration of thromboxane in airways.
We were careful to utilize a low-pressure balloon to
wedge the challenge bronchus, to avoid the balloon
affecting local blood flow by compression. We also
optimized the localization of the samples with the aim of
getting the best recovery. Importantly, the methodology
seemed to maintain the mediator within the bronchial area
challenged, as tested with the local instillation of contrast
medium (Fig. 1). Furthermore, no distribution of contrast
medium into alveoli occurred up to 8min after local
instillation, arguing that the challenge is only bronchial.
There were no macroscopic bleedings and microscopic
bleedings are unlikely to explain the variability of the effects
FIG. 2. Albumin concentration in bronchial lavage after
administration of bradykinin or its vehicle during study
one. (a) Dose-response relationships and (b) maximal
response to bradykinin vs. vehicle, which is the data used
for statistics. Data are shown as mean (SEM).
FIG. 3. IgG concentration in bronchial lavage after
administration of bradykinin or its vehicle during study
one. (a) Dose-response relationships and (b) maximal
response to bradykinin vs. vehicle, which is the data used
for statistics. Data are shown as mean (SEM).
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ane levels would also have been influenced.
Despite these precautions, in study one we could only
demonstrate a dose-dependent effect of bradykinin on
plasma exudation. However, we found a dose-dependent
increase of thromboxane in study two. We therefore
conclude that the lack of effect of plasma exudation in
study two is more related to variability in the effect of
bradykinin in plasma exudation than to technical problems.
We suggest that other mediators inducing plasma exuda-
tion should be used.
It is known from several previous studies in experimental
animals that bradykinin cause exudation of plasma, and
parallel an increase in local thromboxane levels (21). When
the induction of plasma exudation with bradykinin is
severe, it also seems that thromboxane is involved in the
process, since thromboxane antagonists will attenuate the
plasma exudation (26). In study two, we found that
thromboxane B2 (a stable thromboxane A2 metabolite)
was increased after bradykinin even though no changes inthe concentration of plasma macromolecules in bronchial
lavage could be detected. Thus, it seems that in man, the
bradykinin-induced exudation of plasma and thromboxane
release are independent processes.
Bradykinin is a complex mediator causing airway effects
by several mechanisms, including direct bronchial smooth
muscle contraction and plasma exudation, but also indirect
effects on these end organs by the release of other
extracellular mediators, including thromboxane (28,29).
Furthermore, bradykinin has been shown to activate
airway nerves, which may contribute to bradykinin-induced
airway narrowing (15). Asthmatic airways are also more
responsive to bradykinin, which may enhance the effects of
the mediator in vivo (30). Thus, the reduction in lung
function induced by inhaled bradykinin is increased in
asthmatic subjects in general (15), and further enhanced
during experimental rhinovirus infection (31).
Plasma exudation has been argued to possibly contribute
to airway narrowing by causing oedema, but perhaps even
more important to bronchial hyper-responsiveness (32).
Thus, slight thickening of the airway wall may potentiate
the airflow resistance induced by a specific degree of
bronchial smooth muscle shortening (33). This enhance-
FIG. 4. Thromboxane B2 concentration in bronchial
lavage after administration of bradykinin or its vehicle
during study two. (a) Dose-response relationships and
(b) maximal response to bradykinin vs. vehicle, which is
the data used for statistics. Data are shown as mean (SEM).
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reduction of the radius. Plasma exudation may also
contribute to mucus production, since a significant amount
of the extravasated plasma volume enters the airway lumen
(4,34).
Our findings from study one, and those from a previously
published study (19), suggest that bradykinin given into the
airway lumen is quite weak and highly variable in inducing
plasma exudation in humans. This might be explained by
the fact that the airway epithelial layer contains high
concentrations of neutral endopeptidase (NEP 24.11) and
angiotensin-converting enzyme (ACE). These enzymes will
both rapidly degrade bradykinin when reaching the
epithelium. Bradykinin would probably have given a more
pronounced and reproducible plasma exudation if both
NEP24.11 and ACE activities had been blocked by specific
enzyme blockers (27), but with such an experiment, the risk
of systemic effects would be much higher, as we observed
with higher doses of bradykinin in preliminary experiments.
Our overall conclusion is therefore that bradykinin should
not be chosen in studies of plasma exudation in man.
In this paper we present a new method, using a low-
pressure balloon catheter to localize a transbronchoscopychallenge to the bronchial lumen. We have been able with
this methodology to document that local bronchial admin-
istration of a mediator (bradykinin) can induce plasma
exudation, as well as secondary mediator release (throm-
boxane B2). Additional development of this methodology
may give us further opportunity to study mechanisms of
plasma exudation in human airways, and how different
mediators interact with each other to induce such effects.
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